OKO. I. Kryzhanovska

O. I. Kryzhanovska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. I. Kryzhanovska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • L. M. Semenyuk

    Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

    6 shared publications
  • Ye. S. Kozachuk

    Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

    5 shared publications
  • О. І. Крижановська

    Національний медичний університет імені О. О. Богомольця,Київ

    3 shared publications
  • Tetyana Yuzvenko

    Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine

    2 shared publications
  • Т. Ю. Юзвенко

    Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

    2 shared publications
  • D. O. Hovsieiev

    1 shared publication

Latest Publications

  • Open Access

    Autoimmune thyroid diseases and their impact on sexual and reproductive function in young women

    by L. M. Semeniuk, T. Y. Yuzvenko, Y. S. Kozachuk, L. S. Chernukha, O. I. Kryzhanovska, Т. Ю. Юзвенко, О. І. Крижановська

    Objective — to determine the relationship between the characteristics of the hormonal background and signs of FSD in women with ATD in the prediction of the success of future gestation and the formation of POF. Materials and methods. The study design is a prospective study that included 30 women of reproductive age (main group) with ATD and 30 healthy women of reproductive age — the control group. The levels of steroid and peptide hormones, domains of FSD and the ovulatory phase of the menstrual cycle were studied during 9 months of therapy. The presence of female sexual dysfunction was determined using a questionnaire with scoring on an online calculator. The treatment included the use of a complex of herbal remedies recommended for hypoandrogenic ovarian dysfunction. Statistical analysis was performed using the specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. All women in the main group had a combination of signs of FSD with anovulation against the background of clinically significant TPOAb indicators. Correlations were established: statistically significant relationship between desire and 17-OP indicators; arousal and progesterone; orgasm and TPOAb, TSH, progesterone; pain and homocysteine, TSH; FSFI and TSH, between questionnaire scores and hormonal indicators: orgasm and vitamin D; AMH and pleasure, pain, FSFI (p<0.05). After 9 months of therapy, 60.0% (n=18) of the patients in the main group had persistent DHEA-S deficiency. Monitoring of ovulation by ultrasound folliculometry in the main group indicated a negative prognosis for natural pregnancy in 16 (53.3%) of the examined. Conclusions. Familiarity of doctors of related specialties with the problem of autoimmune thyroid pathology and its consequences for the sexual and reproductive health of women can improve their awareness of the individualized prognosis of pregnancy. Pregnancy planning in women with ATD with an emphasis on their age and the value of thyroid antibody titers. Determination of reproductive steroidogenesis along with examination of the thyroid panel. With low DHEA-S indicators — indications for examination of adrenal function.

  • Open Access

    Determining the relationship between hormonal background characteristics and signs of female sexual dysfunction in women with and without endometriosis in the prediction of gestational success

    by L.M. Semeniuk, V.I. Pankiv, Ye.S. Kozachuk, O.I. Kryzhanovska

    Background. Overcoming infertility in young women is recognized as one of the most important tasks of modern medicine. Among the factors that reduce female fertility, endometriosis remains relevant. The widespread prevalence of diseases with common pathogenetic factors has led to the emergence of diseases of “old age” in women of reproductive age. These include, in particular, female sexual dysfunction (FSD). The relationship between FSD and hormonal indicators as prognostic factors of female reproductive health has been little studied to date. The purpose was to determine the relationship between the characteristics of the hormonal background and signs of FSD in women with and without endometriosis in the prediction of the success of future gestation. Materials and me­thods. The study design is a prospective cohort study, which included 130 women of reproductive age. They were divided into 3 groups: group IA (n = 70) — a combination of female sexual dysfunction and extragenital endometriosis, the comparison group IB (n = 30) — female sexual dysfunction without extragenital endometriosis, the control group II (n = 30) — healthy reproductively active women. The end points of the study were levels of pituitary and ovarian hormones, proandrogenic steroids, ovulatory menstrual cycles. These indicators were studied before treatment and at the control periods of therapy — 3, 6, 9 months. The presence of FSD was determined using a questionnaire with scoring on an online calculator, when the female sexual function index was less than 26.55 points. The therapy was aimed at restoring the correct functioning of ovarian steroidogenesis using herbal therapy. Statistical analysis was performed using a specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. A significant normalization of pituitary peptide hormones in the comparison groups occurred in the period from the sixth to the ninth month of therapy. As for the estradiol level, its significant increase was noted in both comparison groups throughout the entire observation period. At the ninth month, the values of progesterone in patients with FSD and endometriosis were significantly higher in than those without it (p = 0.002). Despite the treatment, the estradiol and progesterone levels in the IA group remained significantly lower than in the control group throughout the entire observation period (p < 0.001). In patients without endometriosis (IB group), after 9 months of treatment, only estrogen values were successfully corrected, which were comparable to the control group. Analysis using Dunn’s test with Bonferroni correction showed no statistically significant difference between the IA and IV groups throughout the entire course of treatment (p > 0.05). Correlation analysis revealed that in patients with FSD and endometriosis after 6 months of treatment, changes in the studied hormones statistically significantly correlated with improvements in scores in all domains of the questionnaire. At the control period of 6 months, 20 (66.3 %) women were not ready for safe conception. In the 9-month control period, 16 (53.3 %) patients in this group were not ready for safe motherhood. Conclusions. Women with external-internal endometriosis and FSD and women with FSD alone have different pathogenetic background in the formation of gestational pathology. Therapy of patients with any form of FSD should be personalized. Assessment of FSD domains allows for rapid diagnosis of future gestational risks in women of reproductive age.

  • Open Access

    Management of vitamin D deficiency and hypothyroidism in pre-pregnancy preparation of women with sexual dysfunction associated with endometriosis

    by L. M. Semeniuk, T. Y. Yuzvenko, Y. S. Kozachuk, O. I. Kryzhanovska, Т. Ю. Юзвенко, О. І. Крижановська

    In modern conditions, infertile women have a high percentage of so‑called «diseases of civilization»: autoimmune thyroid disorders, dysmetabolic processes, endometriosis, and female sexual dysfunction. Researchers note the role of vitamin D deficiency or insufficiency in the manifestations of these pathological conditions. The lack of an integrated assessment of health and a clear personalized approach when prescribing treatment gives the pathological process a chronic nature and sometimes leads to a persistent loss of fertility. Objective — to determine the relationship between the features of FSD in women with and without endometriosis and changes in hormonal support of reproductive function during the control periods of therapy. Materials and methods. Study design — prospective cohort study, which included 130 women of reproductive age. Patients were stratified into 3 groups according to diagnosed female sexual dysfunction and external genital endometriosis: Group IA (n=70) — main group — women with a combination of female sexual dysfunction and external genital endometriosis; Group IB (n=30) — comparison group — women with female sexual dysfunction without external genital endometriosis; Group II (n=30) — control group — healthy reproductively active women. Management of low vitamin D levels and thyroid hypofunction was carried out as part of complex therapy for hormonal homeostasis disorders. The study endpoints were: 1. Vitamin D levels, Thyroid peroxidase (TPO) antibody (TPO‑Ab) levels, Thyroid stimulating hormone (TSH) levels, FSD. The indicated indicators were studied before treatment and at the control periods of therapy — 3, 6, 9 months. Biochemical studies were conducted in the clinical laboratory of biochemical, hormonal and immunological studies of the Ukrainian Scientific and Practical Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine. Female sexual dysfunction was assessed using a validated questionnaire with scoring conducted via an online calculator. The presence of FSD was determined when the value of the female sexual function index (FSFI) was less than 26.55 points. Statistical analysis was performed using the specialized statistical software package SPSS 25.0 (StatSoft Inc., USA). Results. In women with FSD, regardless of the presence of endometriosis, a statistically significant increase in vitamin D was achieved 3 months after the start of therapy, with positive dynamics maintained until the 9th month, p<0.001. In the comparison groups, changes in the thyroid hormone profile were noted at these times: a statistically significant decrease in the average values of TPO‑Ab after 3 months (p<0.001) and TSH after 6 months from the start of treatment (p<0.001). Regarding TSH values, a statistically significant difference was observed between patients in groups IA and IB at the 6‑month and 9‑month marks, with levels being higher in IA (p=0.006 and p=0.018, respectively). These laboratory parameters were statistically significantly higher in women with FSD compared to the control group throughout the entire observation period, p0.05. However, in women who persisted FSD, vitamin D deficiency was significantly more often detected (p<0.05). Using binary logistic regression, it was found that only the maintenance of functionally elevated TSH levels was a predictive factor for the maintenance of FSD in this cohort of patients. Linear regression analysis showed that in patients with endometriosis, only increased vitamin D levels significantly improved scores in all categories of the FSD questionnaire. Conclusions. Combined correction of vitamin D and TSH levels allows to achieve a positive therapeutic effect in women with both endometriosis and monoform. Reducing TSH levels in women with and without endometriosis significantly affects the frequency of detection of VSD against the background of treatment and improves its manifestations in the categories of «Desire», «Lubrication», «Orgasm» and «Pain» in patients without endometriosis. Therefore, the preservation of functionally elevated TSH levels is a prognostic factor for the preservation of FSD in women. Endometriosis worsens the response of the woman’s body to the prescribed treatment, which requires individualized medical tactics at the pre‑gravid stage.

  • Open Access

    Individualized approach in the management of women with female sexual dysfunction, external genital endometriosis and hyperhomocysteinemia

    by L. M. Semenyuk, Y. S. Kozachuk, O. I. Kryzhanovska, О. І. Крижановська

    The problem of treatment of endometriosis in women of reproductive age remains an urgent task for obstetricians and gynecologists, as it has a direct impact on women’s ability to conceive. Overcoming the demographic crisis in Ukraine requires doctors to find new methods and techniques in a personalized approach to the treatment of women with endometriosis. The presence of comorbid pathology in endometriosis, in particular hyperhomocysteinemia (HHC) and female sexual dysfunction (FSD), necessitates individualization of the management of such patients. Objective — to determine the effect of surgical treatment of women with external‑intraoral endometriosis and female sexual dysfunction and hyperhomocysteinemia on the characteristics of their hormonal homeostasis and indicators of FSD. Materials and methods. The study included 19 patients with external‑intrinsic endometriosis and female sexual dysfunction and hyperhomocysteinemia with homozygous form of MTRF gene polymorphism. Surgical intervention in the form of laparoscopic cystectomy was performed in 12 patients (group I). 7 patients refused to undergo surgery (group II). Surgical intervention was performed 6 months after the start of treatment. The hormonal status and parameters of the FSD were studied according to the results of a questionnaire at the time of treatment, 6 months after the start of conservative therapy, and 3 months after surgery. Results. At 3 months after surgery, the values of vitamin D, FSH, LH, estradiol, progesterone, free T, DHEA‑S and 17‑OH were statistically significantly higher in women of group I compared with patients who did not undergo surgery — II (p<0.05), and the levels of homocysteine, TSH, prolactin were lower (p<0.05). In patients of group I, a statistically significant increase in questionnaire scores was noted after surgery compared with patients who did not undergo surgery at a significance level of p<0.001. Against the background of the total duration of treatment (6 months of conservative therapy + 3 months of combined treatment — conservative therapy + surgery) in patients of group I with a homozygous mutation, it was possible to achieve normalization of the FSD in all 12 (100.0%) patients. In patients who did not undergo surgery, no normalization of FSD was observed. Conclusions. The treatment of women with FSD and external genital endometriosis should be individualized, taking into account the entire clinical problem, including the impact of the disease and the impact of its treatment on the quality of life. Pregravidar preparation of women with LBP and BPH and hypoandrogenism in homozygous carriage of MTRF polymorphism genes should include surgical removal of ovarian endometrioma to improve LBP and hormonal background for pregnancy.


  • Open Access

    Physiological characteristics of reproductive-age patients with female sexual dysfunction and endometriosis (a comparison of clinical and laboratory parameters in different study groups)

    by O. I. Kryzhanovska, L. M. Semeniuk

    Endometriosis is an estrogen-dependent inflammatory disease that affects 5–10 % of reproductive-age women. About two-thirds of women with endometriosis have sexual dysfunction caused by dyspareunia, which negatively affects the quality of life and mental health of a woman. The aim of the study is to identify differences in clinical and laboratory parameters in study groups of reproductive-age female patients with the aim of obtaining information about specifics of the female sexual dysfunction (FSD) development in women with endometriosis. Materials and methods. The examination results of the hormonal profile, sexual functional index and other laboratory markers were analyzed in 130 women of active reproductive age: Group I (n = 100) – the main group – women with manifestations of FSD including subgroup IA (n = 70) – women with FSD and external genital endometriosis and IB subgroup (n = 30) – women with FSD alone; Group II (n = 30) – healthy women. Results. Women with endometriosis combined with FSD (IA) exhibited a reproductive hormonal profile different from that in women with FSD (IB), which was seen by a significant difference in follicle-stimulating hormone (FSH), estradiol, free testosterone and dehydroepiandrosterone sulfate values (p = 0.001, p = 0.039, p = 0.035 and p = 0.035, respectively). Vitamin D deficiency and hyperhomocysteinemia, the presence of antibodies to thyroperoxidase and functional hyperprolactinemia have been detected in all the women with FSD signs, regardless of the concomitant endometriosis presence. Post-hoc analysis (Mann–Whitney test) has shown that the mean scores for all categories of the Female Sexual Function Index (FSFI) questionnaire were statistically significantly higher in Group IA patients compared to those in Group II patients (p < 0.001). Conclusions. The hormonal profile of women with endometriosis is characterized by increased levels of FSH, estradiol, free testosterone and dehydroepiandrosterone sulfate as compared to that in women with FSD alone, however it does not prevent the development of FSD signs in them and is accompanied by different indicators of the FSFI domains. Ендометріоз – естрогензалежне запальне захворювання, що уражає 5–10 % жінок репродуктивного віку. Майже дві третини жінок з ендометріозом мають сексуальну дисфункцію, що зумовлена диспареунією, негативно впливає на якість життя та психічне здоров’я. Мета роботи – визначити відмінності клініко-лабораторних показників у різних групах пацієнток репродуктивного віку для отримання інформації щодо особливостей формування підґрунтя розвитку жіночої сексуальної дисфункції (ЖСД) у хворих на ендометріоз. Матеріали і методи. Проаналізували результати обстеження гормонального фону, індексу сексуальної дисфункції (ІСД) та інших лабораторних маркерів 130 жінок активного репродуктивного віку. Обстежених поділили на групи: у І (n = 100) – основну групу – залучили жінок із ЖСД, з-поміж них розрізняли ІА підгрупу (n = 70) – жінки із ЖСД і зовнішнім генітальним ендометріозом і ІВ підгрупу (n = 30) – жінки тільки з ЖСД; у ІІ групу (n = 30) ввійшли здорові жінки. Результати. Гормональний репродуктивний фон жінок з ендометріозом, що поєднаний із ЖСД (група ІА), відрізняється від такого в пацієнток із моноформою ЖСД (група ІВ). Це виявили за достовірною різницею рівнів фолікулостимулювального гормона, естрадіолу, тестостерону вільного та дегідроепіандростерон-сульфату – р = 0,001, р = 0,039, р = 0,035 та р = 0,035 відповідно. У всіх жінок з ознаками ЖСД (незалежно від наявності супутнього ендометріозу) виявили недостатність вітаміну D, гіпергомоцистеїнемію, антитіла до тиреопероксидази, діагностували функціональну гіперпролактинемію. Апостеріорний аналіз (критерій Манна–Вітні) показав, що у пацієнток групи ІА середні значення балів за всіма категоріями анкети визначення ІСД статистично значущо вищі порівняно з параметрами обстежених із групи ІВ (р < 0,001). Висновки. Гормональний фон жінок із зовнішнім генітальним ендометріозом і ЖСД порівняно з пацієнтками з моноформою ЖСД характеризується підвищеними рівнями фолікулостимулювального гормона, естрадіолу, тестостерону вільного та дегідроепіандростерон-сульфату, при цьому не запобігає формуванню у них ознак ЖСД і супроводжується різними...


  • Open Access

    Clinical characteristics of women with female sexual dysfunction and endometriosis

    by O.I. Kryzhanovska, Ukraine Kyiv City Maternity Hospital No 5

    Endometriosis is a disease characterized by the presence of endometrial tissue outside the uterine cavity. Endometriosis refers to estrogen-dependent diseases, clinically manifested by dysmenorrhea, dyspareunia, dyschezia. Decreased fertility in women with endometriosis is associated with the presence of chronic inflammation that leads to pelvic pain and infertility. It is believed that endometriosis is associated with mood disorders such as anxiety or depression, which can create a pathological background for sexual dysfunction. Purpose - to establish the relationship between female sexual dysfunction (FSD) and external genital endometriosis in order to optimize women's pregravid preparation. Materials and methods. 100 women of reproductive age were examined. The main group (the Group I) consisted of 70 women who had external genital endometriosis (diagnosed by ultrasound examination of the pelvic organs, ovarian endometrioma size up to 5 cm). The main group was divided into 2 subgroups: IA - 40 women with FSD and endometriosis; IB - 30 women with FSD without endometriosis. The control group (the Group II) included 30 healthy reproductively active women in the pre-gravid stage. In the course of the study, the nosological unit approved by the World Health Organization (1999) was taken into account and taken as a basis - FSD, which include disorders of desire, arousal and reaching orgasm, dyspareunia and vaginismus. The results of clinical and biochemical studies were processed using a specialized package of statistical programs Statistica 8.0 (StatSoft Inc., USA). The following criteria were used for statistical processing of the obtained data: Kruskal-Wallis test, Mann-Whitney U test, Pearson chi-squared (χ2) test, Wilcoxon test. Results. The analysis of the definition of FSD in women with endometriosis clearly indicates the presence of signs of FSD in all areas and is statistically significantly different from the indicator of healthy women. Conclusions. There is a relationship between endometriosis and FSD that can be determined using the FSFI Questionnaire Calculator. Since FSD and endometriosis have a polymorbid background, treatment should be carried out by a multidisciplinary team of doctors and be personalized. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the author.


  • Open Access

    CHARACTERISTICS OF CHANGES IN THE HORMONAL PROFILE OF FEMALE SEXUAL DYSFUNCTION AND GENITAL ENDOMETRIOSIS IN THE TREATMENT PROCESS

    by O. I. Kryzhanovska, D. O. Hovsieiev

    Vitamin D deficiency and hormonal disbalance could be involved in the development of endometriosis and female sexual dysfunction (FSD). The purpose of the study – to determine the characteristics of changes in the hormonal profile of women with FSD and external genital endometriosis. The evaluation of peptide, steroid hormones, vitamin D, and homocysteine level was conducted on the 5–7th days of the menstrual cycle at the beginning of the study and 3, 6, 9 months after the treatment. A value of p < 0.0085 was considered significant difference between the intervention group (n=70) and control group (healthy women, n=30) under comparison. Results. Statistical analysis (Friedman’s test) of the dynamics of laboratory indicators during the control periods in group I showed a significant gradual increase in the levels of dehydroepiandrosterone sulfate (DHEA-S), free testosterone, estradiol, progesterone, FSH, LH, and Vitamin D (p<0.001) and decrease – 17-ОНР, Prolactin, thyroid-stimulating hormone (TSH), antibodies to thyroperoxidase (Anti-TPO) and homocysteine (p<0.001) against the background of the treatment. Normalization of the level of vitamin D was observed starting at the 6th and 9th months of observation in 32.9% (n=23) and 80.0% (n=56) and was significantly higher compared to the 6th month – χ2 = 29.75, p<0.001. Reference values of the homocysteine level in the 1st group were also achieved starting from the 6th month, but the share of such women was only 20.0% (n=14). In the 9th month of treatment, the proportion of patients with normhomocysteinemia increased significantly to 38.6% (n=27), χ2 = 4.97, p=0.026. Dynamics of changes in the hormonal profile of the thyroid gland after 3 months was characterized by a significant decrease in the initial levels of TSH level (on the 3rd, 6th, 9th months, p<0.001). The optimization of female sexual function occurs in the 9th month of therapy and is accompanied by a reliable normalization of the index of sexual dysfunction. In this term, the indicator of the sexual dysfunction index approaches the norm (26.55), which is classified as a sign of the absence of female sexual dysfunction. Метою дослідження було визначення особливостей змін гормонального профілю жінок із жіночою сексуальною дисфункцією (ЖСД) та зовнішнім генітальним ендометріозом (ЗГЕ) у процесі лікування. Було проведено аналіз рівня пептидних, стероїдних гормонів, вітаміну Д, гомоцистеїну на 5–7 дні менструального циклу, а також через 3, 6, 9 місяців після фармакологічної корекції у 70 жінок активного репродуктивного віку із ЖСД та ЗГЕ (І група) і 30 здорових жінок (ІІ група). У результаті проведеного лікування нормалізація рівня вітаміну Д відзначалась через 6 і 9 місяців спостереження у 32,9% і 80,0% (р<0,001) жінок; на 9-му місяці нормогомоцистеїнемія спостерігалась у 38,6% жінок (р=0,026 стосовно контролю). Оптимізація сексуальної функції жінок відбувається на 9-му місяці терапії і супроводжується достовірною нормалізацією індексу сексуальної дисфункції (ІСД). У цей термін показник ІСД наближається до показника норми (26,55), що класифікується як ознака відсутності ЖСД.